Collins Helen Louise 4
4 · Enliven Therapeutics, Inc. · Filed Feb 17, 2026
Research Summary
AI-generated summary of this filing
Enliven (ELVN) CMO Helen Collins Receives 175,000-Share Award
What Happened
Helen Louise Collins, Chief Medical Officer of Enliven Therapeutics (ELVN), received two equity awards on February 12, 2026: 25,000 restricted stock units (RSUs) and 150,000 derivative awards (reported as a derivative grant). Both awards were issued at $0.00 per share (no cash paid).
Key Details
- Transaction date: 2026-02-12; Filing date: 2026-02-17 (filing appears late relative to the 2-business-day Form 4 deadline).
- Awards: 25,000 RSUs (acquired, $0) and 150,000 derivative shares (acquired, $0); total granted = 175,000 units.
- Reported value paid: $0.00 for both grants.
- Shares owned after the transaction: not stated in the information provided in this summary (not reported here).
- Footnotes:
- F1 (applies to RSUs): Each RSU is a contingent right to one share. Vesting: 1/4 vests on March 1, 2027, then 1/16th vests each June 1, Sept 1, Dec 1, and March 1 thereafter, subject to continued service.
- F2 (applies to derivative award/option): 1/4 of the option shares vest on February 12, 2027, then 1/48th vest each month thereafter, subject to continued service.
Context
These are awards (compensation grants), not open-market purchases or sales, so they reflect equity compensation rather than an immediate insider buy/sell signal. The RSUs convert to shares only as they vest; the derivative award appears to be an option-like grant with a separate monthly vesting schedule. The filing date (Feb 17) is later than the transaction date (Feb 12), indicating a late Form 4 filing, which investors should note for transparency/timeliness considerations.
Insider Transaction Report
- Award
Common Stock
[F1]2026-02-12+25,000→ 25,000 total - Award
Stock Option (right to buy)
[F2]2026-02-12+150,000→ 150,000 totalExercise: $27.16Exp: 2036-02-12→ Common Stock (150,000 underlying)
Footnotes (2)
- [F1]These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 1/4th of the RSUs will vest on March 1, 2027 and 1/16th of the RSUs will vest each June 1, September 1, December 1, and March 1 thereafter, subject to the Reporting Person continuing as a service provider through each such date.
- [F2]1/4th of the shares subject to the option will vest on February 12, 2027 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.